Home > Insider Trading > Filing (0001546927-15-000263)

Filing Details

Accession Number:: 0001546927-15-000263
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-10-20 14:18:07
Reporting Period:: 2015-10-19

Filing Date:: 2015-10-20
Accepted Time:: 2015-10-20 14:18:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006281	Protalix Biotherapeutics Inc.	PLX	Biological Products, (No Disgnostic Substances) (2836)	650643773

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1444043	Camber Capital Management Llc	101 Huntington Avenue Suite 2550 Boston MA 02199		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-10-19	4,000,000	$1.00	13,274,577	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2015-10-19	423	$1.03	13,275,000	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

Securities reported herein for Camber Capital Management LLC (the "LLC" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 25, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.
Of the securities reported for this transaction, 3,862,000 shares of Common Stock were purchased for the account of the Master Fund, 27.200 shares of Common Stock were purchased for the account of the Fund, and 110,800 shares of Common Stock were purchased for the account of the Managed Account.
Of the securities reported for this transaction, 408 shares of Common Stock were purchased for the account of the Master Fund, 3 shares of Common Stock were purchased for the account of the Fund, and 12 shares of Common Stock were purchased for the account of the Managed Account.
As of the closing of trading on October 19, 2015, 12,815,503 shares of Common Stock were held for the account of the Master Fund, 90,260 shares of Common Stock were held for the account of the Fund, and 369,237 shares of Common Stock were held for the account of the Managed Account.